Andrew Williams counsels clients in patent prosecution and patent litigation with a focus in the areas of biotechnology, pharmaceuticals and molecular diagnostics. His more than seventeen years of extensive experience ranges from counseling clients regarding the Biologics Price Competition and Innovation Act (“BPCIA”); patent prosecution for large, small, and university clients; and litigation before the Patent Trial and Appeal Board (“PTAB”) and in federal district court. Andrew has represented large pharmaceutical and diagnostic clients, biotechnology start-up companies and universities in fields including biological therapeutics, neuropeptides, molecular diagnostics, biosensors, reagents for diagnostics and next-generation sequencing (NGS) and food-based products.

Andrew is an active member of the IP community and has authored articles for various legal publications including Law360, Intellectual Property Magazine, Intellectual Property Today, and Expert Opinion on Therapeutic Patents and Biosimilar Developments. In particular, Andrew has written extensively on issues specific to AIA-related PTAB trials, with a particular focus on life science-related IPRs and PGRs; the emergence of BPCIA-related biosimilars and corresponding patent resolution strategies; efforts to draft legislation to curb abusive patent litigation; and ethical issues related to patent practice.

Prior to joining the firm, Andrew was a partner at McDonnell Boehnen Hulbert & Berghoff LLP. He was also a founding member and Chair of the firm’s PTAB Trials Practice Group.

  • PTAB Bar Association
    • Member of the Program Committee
  • Intellectual Property Owner’s Association 
    • Member of the U.S. Patent Law committee (voting) and Pharmaceutical & Biotechnology Issues Committee (non-voting)
  • The Richard Linn American Inn of Court
  • Federal Circuit Bar Association 
    • Member of the Amicus Committee
  • American Bar Association 
    • Member of the Patents in the Chemical and Life Sciences Committee
  • American Association for the Advancement of Science
  • Top Author in JD Supra Readers’ Choice 2017 (“Pharmaceutical Industry”) and 2016 (“Patents”)
  • Extern, Hon. Richard Linn, U.S. Court of Appeals for the Federal Circuit


  • “The State Of Pharma Litigation After The Supreme Court's TC Heartland Case,” Life Science Leader (June 2018)
  • “Supreme Court Holds that IPR Proceedings do not Violate Article III or the Seventh Amendment in Oil States v. Greene’s Energy,” MBHB Snippets Alert (April 2018)
  • “Motions to Amend at the PTAB after Aqua Products, Inc. v. Matal – What’s a Patent Owner to Do?,” MBHB Snippets Newsletter (Winter 2018)
  • “CAFC Shifts the Burden for IPR Claim Amendments from the Patent Owner to the Petitioner,” MBHB Snippets Alert (October 2017)
  • “Reports of the Death of the Patent Dance Have Been Slightly Exaggerated,” The Pharma Letter (July 2017)
  • “SCOTUS: Supreme Court Lifts Biosimilars by Allowing Early Commercial Marketing Notice,” MBHB Snippets Alert (June 2017)
  • “Can SCOTUS solve the biosimilar ‘enigma’?,” Intellectual Property Magazine (March 2017)
  • “10 Years Of MedImmune: How Patent Owners Fared,” Law360.com (February 2017)
  • “Post-Grant Review Estoppel – Looking Forward by Looking Back at Estoppel in Inter-Partes and Covered-Business-Method Review,” MBHB Snippets Newsletter (Winter 2017)
  • “Some Clarity for Biosimilar Applicants,” Intellectual Property Magazine (September 2016)
  • Cuozzo Speed Technologies, LLC v. Lee – Supreme Court Holds Status Quo,” MBHB Snippets Alert (June 2016)
  • “Supreme Court Rules District Courts to Have More Discretion in Finding Willful Patent Infringement by Malicious Pirates,” MBHB Snippets Alert (June 2016)
  • “The PTAB at the Supreme Court – and the Federal Circuit’s Response,” IP Watchdog (April 2016)
  • “Standing Alone – The Current Status of the BPCIA’s Notice of Commercial Marketing,” MBHB Snippets Newsletter (Spring 2016)
  • “One Year After In re Cuozzo,” Intellectual Property Magazine Online (March 2016)
  • “The PTAB and the Federal Circuit – One Year Later,” MBHB Snippets Newsletter (Winter 2016)
  • “5 Questions To Ask About Biosimilars In 2016” Biosimilar Development Online (January 2016)
  • “The BIO International Convention in Philadelphia,” Intellectual Property Magazine (September 2015)
  • "Amgen v. Sandoz - Did Fed. Circ. Doom The New Biosimilar Approval Pathway?," MBHB Snippets Newsletter (Summer 2015)
  • “Biosimilars at the Federal Circuit – Will this be the Last Dance?,” IP Watchdog (June 2015)
  • “Biosimilars at the Federal Circuit – Can the Parties Be Compelled to Dance?,” BIOTechNOW (June 2015)
  • "First U.S. Biosimilar Application Approved — But What About the Patent Issues?,” iBIO's Biological Quarterly (March 2015)
  • “Federal Circuit Sides with Patent Office in First IPR Final Written Decision Review,” MBHB Snippets Alert (February 2015)
  • "Just What Does It Take to Amend Claims Before the PTAB?: Lessons Learned From the Board," MBHB Snippets Newsletter (Winter 2015)
  • Teva Pharmaceuticals USA, Inc. v. Sandoz Inc. – U.S. Supreme Court Requires Trial Court’s Findings of Fact in Claim Construction Be Given Deference,” MBHB Snippets Alert (January 2015)
  • "How would patent reform legislation in the United States impact the pharmaceutical industry?," Expert Opinion on Therapeutic Patents (November 2014)
  • "Patent Reform Legislation Off The Table For Now," BIOTechNOW (June 2014)
  • "Senate Judiciary Committee Takes Up, Then Tables, Patent Reform," Today's General Counsel (April 2014)
  • "PatentDocs.org: A Rebuttal to The Economist's 'Stalking Trolls'," InnovationAlliance.net (March 2014)

  • “Top Stories at the PTAB: What You Need to Know,” MBHB webinar, March, 2018 
  • "Strategies for Coping with the Evolving Landscape of Biosimilars Patent Resolution in the United States," 4th Biologics & Biosimilars Congress, March, 2018
  • "Advanced IPR Topics," Chicago Regional IPR Seminar of the PTAB Bar Association, December, 2017 
  • "Show Me the Money: Strategies to Overcome Valuation Challenges," American Conference Institute’s Summit on IP Due Diligence (Comprehensive and Practical Tips for Pharmaceutical, Biotechnology, and Medical Device Professionals), November, 2017 
  • “Drafting Patent Counsel Engagement and Disengagement Letters," Strafford Webinar, July 2017 
  • “Post-Grant Review at the PTAB: What Petitioners and Patent Owners are Doing and What Lies Ahead?,” MBHB webinar, March, 2017 
  • “Strategies for Addressing Intellectual Property Barriers to Biosimilar Marketing,” 3rd Biologics & Biosimilars Congress, March, 2017
  • “The PTAB Front and Center at the Federal Circuit and the Supreme Court: The First Year of Appellate Review,” MBHB webinar, May, 2016
  • “The Evolving World of Biosimilars Litigation,” MBHB webinar, September, 2015
  • “Harmonization of USPTO Ethical Standards in the Post-AIA Era” at the John Marshall Law School Ethics in the Practice of Law symposium, April 2015
  • “Inter Partes Review (IPR) at the Patent Trial and Appeal Board” at the Northwestern Law IP Symposium, March 2015
  • “Prevailing Before the PTAB “Death Squad”: Practical Considerations for Petitioners and Patent Holders,” MBHB webinar, February 2015
  • “Attorney's Fees, Costs and Other Fee-Shifting Measures in Patent and Trademark Litigation” webinar, sponsored by the ABA Center for Professional Development, February 2015
  • “Reviewing Fact Issues of Claim Construction – Will the Supreme Court Defer to Federal Circuit Precedent?” ABA Section of Litigation Roundtable, June 2014
  • "‘Standing Out’ – The Supreme Court’s Redefined Standard for Fee Shifting in Patent Litigation, and How It Might Impact ‘Patent Troll’ Litigation” MBHB webinar, June 2014
  • Panelist for “Eli Lilly and the Canadian NAFTA Challenge” at the Public Citizen and American University Washington College of Law’s Secondary Use Pharmaceutical Patents: Litigation and Trade Policy Briefing, June 2014
  • “Ethical Considerations in Patenting Biotechnological Inventions” at the John Marshall Law School Ethics in the Practice of Law symposium, April 2014
  • “Solving the ‘NPE Problem’ – Legislative Proposals” at the Northwestern Law IP Symposium, February 2014
  • “Proposed Patent Reform Legislation: How it May Impact You (Especially if You Are Not Considered to be a “Patent Troll”), MBHB webinar, February 2014
  • "New USPTO Rules of Professional Conduct – Harmonization of Ethical Standards,” Corporate Counsel committee of the Intellectual Property Law Association of Chicago, January 2014

Expand All
Andrew Williams counsels clients in patent prosecution and patent litigation with a focus in the areas of biotechnology, pharmaceuticals and molecular diagnostics. His more than seventeen years of extensive experience ranges from counseling clients regarding the Biologics Price Competition and Innovation Act (“BPCIA”); patent prosecution for large, small, and university clients; and litigation before the Patent Trial and Appeal Board (“PTAB”) and in federal district court. Andrew has represented large pharmaceutical and diagnostic clients, biotechnology start-up companies and universities in fields including biological therapeutics, neuropeptides, molecular diagnostics, biosensors, reagents for diagnostics and next-generation sequencing (NGS) and food-based products.

Andrew is an active member of the IP community and has authored articles for various legal publications including Law360, Intellectual Property Magazine, Intellectual Property Today, and Expert Opinion on Therapeutic Patents and Biosimilar Developments. In particular, Andrew has written extensively on issues specific to AIA-related PTAB trials, with a particular focus on life science-related IPRs and PGRs; the emergence of BPCIA-related biosimilars and corresponding patent resolution strategies; efforts to draft legislation to curb abusive patent litigation; and ethical issues related to patent practice.

Prior to joining the firm, Andrew was a partner at McDonnell Boehnen Hulbert & Berghoff LLP. He was also a founding member and Chair of the firm’s PTAB Trials Practice Group.

  • PTAB Bar Association
    • Member of the Program Committee
  • Intellectual Property Owner’s Association 
    • Member of the U.S. Patent Law committee (voting) and Pharmaceutical & Biotechnology Issues Committee (non-voting)
  • The Richard Linn American Inn of Court
  • Federal Circuit Bar Association 
    • Member of the Amicus Committee
  • American Bar Association 
    • Member of the Patents in the Chemical and Life Sciences Committee
  • American Association for the Advancement of Science
  • Top Author in JD Supra Readers’ Choice 2017 (“Pharmaceutical Industry”) and 2016 (“Patents”)
  • Extern, Hon. Richard Linn, U.S. Court of Appeals for the Federal Circuit
  • “The State Of Pharma Litigation After The Supreme Court's TC Heartland Case,” Life Science Leader (June 2018)
  • “Supreme Court Holds that IPR Proceedings do not Violate Article III or the Seventh Amendment in Oil States v. Greene’s Energy,” MBHB Snippets Alert (April 2018)
  • “Motions to Amend at the PTAB after Aqua Products, Inc. v. Matal – What’s a Patent Owner to Do?,” MBHB Snippets Newsletter (Winter 2018)
  • “CAFC Shifts the Burden for IPR Claim Amendments from the Patent Owner to the Petitioner,” MBHB Snippets Alert (October 2017)
  • “Reports of the Death of the Patent Dance Have Been Slightly Exaggerated,” The Pharma Letter (July 2017)
  • “SCOTUS: Supreme Court Lifts Biosimilars by Allowing Early Commercial Marketing Notice,” MBHB Snippets Alert (June 2017)
  • “Can SCOTUS solve the biosimilar ‘enigma’?,” Intellectual Property Magazine (March 2017)
  • “10 Years Of MedImmune: How Patent Owners Fared,” Law360.com (February 2017)
  • “Post-Grant Review Estoppel – Looking Forward by Looking Back at Estoppel in Inter-Partes and Covered-Business-Method Review,” MBHB Snippets Newsletter (Winter 2017)
  • “Some Clarity for Biosimilar Applicants,” Intellectual Property Magazine (September 2016)
  • Cuozzo Speed Technologies, LLC v. Lee – Supreme Court Holds Status Quo,” MBHB Snippets Alert (June 2016)
  • “Supreme Court Rules District Courts to Have More Discretion in Finding Willful Patent Infringement by Malicious Pirates,” MBHB Snippets Alert (June 2016)
  • “The PTAB at the Supreme Court – and the Federal Circuit’s Response,” IP Watchdog (April 2016)
  • “Standing Alone – The Current Status of the BPCIA’s Notice of Commercial Marketing,” MBHB Snippets Newsletter (Spring 2016)
  • “One Year After In re Cuozzo,” Intellectual Property Magazine Online (March 2016)
  • “The PTAB and the Federal Circuit – One Year Later,” MBHB Snippets Newsletter (Winter 2016)
  • “5 Questions To Ask About Biosimilars In 2016” Biosimilar Development Online (January 2016)
  • “The BIO International Convention in Philadelphia,” Intellectual Property Magazine (September 2015)
  • "Amgen v. Sandoz - Did Fed. Circ. Doom The New Biosimilar Approval Pathway?," MBHB Snippets Newsletter (Summer 2015)
  • “Biosimilars at the Federal Circuit – Will this be the Last Dance?,” IP Watchdog (June 2015)
  • “Biosimilars at the Federal Circuit – Can the Parties Be Compelled to Dance?,” BIOTechNOW (June 2015)
  • "First U.S. Biosimilar Application Approved — But What About the Patent Issues?,” iBIO's Biological Quarterly (March 2015)
  • “Federal Circuit Sides with Patent Office in First IPR Final Written Decision Review,” MBHB Snippets Alert (February 2015)
  • "Just What Does It Take to Amend Claims Before the PTAB?: Lessons Learned From the Board," MBHB Snippets Newsletter (Winter 2015)
  • Teva Pharmaceuticals USA, Inc. v. Sandoz Inc. – U.S. Supreme Court Requires Trial Court’s Findings of Fact in Claim Construction Be Given Deference,” MBHB Snippets Alert (January 2015)
  • "How would patent reform legislation in the United States impact the pharmaceutical industry?," Expert Opinion on Therapeutic Patents (November 2014)
  • "Patent Reform Legislation Off The Table For Now," BIOTechNOW (June 2014)
  • "Senate Judiciary Committee Takes Up, Then Tables, Patent Reform," Today's General Counsel (April 2014)
  • "PatentDocs.org: A Rebuttal to The Economist's 'Stalking Trolls'," InnovationAlliance.net (March 2014)

  • “Top Stories at the PTAB: What You Need to Know,” MBHB webinar, March, 2018 
  • "Strategies for Coping with the Evolving Landscape of Biosimilars Patent Resolution in the United States," 4th Biologics & Biosimilars Congress, March, 2018
  • "Advanced IPR Topics," Chicago Regional IPR Seminar of the PTAB Bar Association, December, 2017 
  • "Show Me the Money: Strategies to Overcome Valuation Challenges," American Conference Institute’s Summit on IP Due Diligence (Comprehensive and Practical Tips for Pharmaceutical, Biotechnology, and Medical Device Professionals), November, 2017 
  • “Drafting Patent Counsel Engagement and Disengagement Letters," Strafford Webinar, July 2017 
  • “Post-Grant Review at the PTAB: What Petitioners and Patent Owners are Doing and What Lies Ahead?,” MBHB webinar, March, 2017 
  • “Strategies for Addressing Intellectual Property Barriers to Biosimilar Marketing,” 3rd Biologics & Biosimilars Congress, March, 2017
  • “The PTAB Front and Center at the Federal Circuit and the Supreme Court: The First Year of Appellate Review,” MBHB webinar, May, 2016
  • “The Evolving World of Biosimilars Litigation,” MBHB webinar, September, 2015
  • “Harmonization of USPTO Ethical Standards in the Post-AIA Era” at the John Marshall Law School Ethics in the Practice of Law symposium, April 2015
  • “Inter Partes Review (IPR) at the Patent Trial and Appeal Board” at the Northwestern Law IP Symposium, March 2015
  • “Prevailing Before the PTAB “Death Squad”: Practical Considerations for Petitioners and Patent Holders,” MBHB webinar, February 2015
  • “Attorney's Fees, Costs and Other Fee-Shifting Measures in Patent and Trademark Litigation” webinar, sponsored by the ABA Center for Professional Development, February 2015
  • “Reviewing Fact Issues of Claim Construction – Will the Supreme Court Defer to Federal Circuit Precedent?” ABA Section of Litigation Roundtable, June 2014
  • "‘Standing Out’ – The Supreme Court’s Redefined Standard for Fee Shifting in Patent Litigation, and How It Might Impact ‘Patent Troll’ Litigation” MBHB webinar, June 2014
  • Panelist for “Eli Lilly and the Canadian NAFTA Challenge” at the Public Citizen and American University Washington College of Law’s Secondary Use Pharmaceutical Patents: Litigation and Trade Policy Briefing, June 2014
  • “Ethical Considerations in Patenting Biotechnological Inventions” at the John Marshall Law School Ethics in the Practice of Law symposium, April 2014
  • “Solving the ‘NPE Problem’ – Legislative Proposals” at the Northwestern Law IP Symposium, February 2014
  • “Proposed Patent Reform Legislation: How it May Impact You (Especially if You Are Not Considered to be a “Patent Troll”), MBHB webinar, February 2014
  • "New USPTO Rules of Professional Conduct – Harmonization of Ethical Standards,” Corporate Counsel committee of the Intellectual Property Law Association of Chicago, January 2014